VEA
PRLD icon

Virtus ETF Advisers’s Prelude Therapeutics PRLD Stock Holding History

Virtus ETF Advisers’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,180
Closed -$160K – 477
2022
Q3 		$160K Buy
24,180
+175
+0.7% +$1.18K 0.06% 344
2022
Q2 		$125K Buy
24,005
+10,957
+84% +$55.8K 0.05% 373
2022
Q1 		$90K Sell
13,048
-767
-6% -$7.01K 0.04% 319
2021
Q4 		$172K Buy
13,815
+7,523
+120% +$122K 0.07% 273
2021
Q3 		$197K Sell
6,292
-330
-5% -$10.7K 0.09% 273
2021
Q2 		$190K Buy
+6,622
New +$236K 0.08% 370

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Virtus ETF Advisers's PRLD Position: Q4 2022 in Review

Virtus ETF Advisers sold out of Prelude Therapeutics (PRLD) in Q4 2022, closing a stake of 24,180 shares — an estimated $160K sold.

Virtus ETF Advisers first reported a position in PRLD in Q2 2021 and held it in 6 quarters. The position peaked at $197K in Q3 2021. 60 funds tracked by Wall St. Rank hold PRLD as of Q4 2022.

  • Virtus ETF Advisers reported no remaining Prelude Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Virtus ETF Advisers sold 24,180 Prelude Therapeutics shares in Q4 2022, an estimated $160K.
  • Virtus ETF Advisers first reported a position in Prelude Therapeutics in Q2 2021 and held it in 6 quarters.
  • Virtus ETF Advisers's Prelude Therapeutics position peaked at $197K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2022.

Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.